Adjuvant chemotherapy for resected non-small cell lung cancer

被引：36

作者：

Booth, Christopher M. ^{[1
]}

Shepherd, Frances A. ^{[1
]}

机构：

[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada

来源：

JOURNAL OF THORACIC ONCOLOGY | 2006年 / 1卷 / 02期

关键词：

D O I：

10.1097/01243894-200602000-00016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite improved surgical techniques, relapse and mortality rates remain high among patients with resected non-small cell lung cancer. Numerous randomized controlled trials in the 1980s and 1990s were unable to demonstrate a consistent survival benefit for adjuvant chemotherapy. However, in the past 2 years, the results of three pivotal trials have unequivocally shown the benefit to adjuvant treatment in resected non-small cell lung cancer. In this review, we describe early adjuvant trials and highlight the recent landmark studies in this disease. The focus of ongoing and future research efforts is also discussed.

引用

页码：180 / 187

页数：8

共 47 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2]

BEZJAK A, 2003, LUNG CANCER S4, V41, pS20

[3]

Blackhall Fiona H, 2005, Treat Respir Med, V4, P71, DOI 10.2165/00151829-200504020-00001

[4]

BRIA E, 2004, ANN ONCOL, V15, pA646

[5]

Burdett S, 1998, LANCET, V352, P257

[6]

DAUTZENBERG B, 1995, CANCER, V76, P779, DOI 10.1002/1097-0142(19950901)76:5<779::AID-CNCR2820760511>3.0.CO

[7]

2-O

[8]

De Vita V.T., 2004, CANC PRINCIPLES PRAC, V7th

[9] Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials [J].

Di Maio, M ;

Gridelli, C ;

Gallo, C ;

Shepherd, F ;

Piantedosi, FV ;

Cigolari, S ;

Manzione, L ;

Illiano, A ;

Barbera, S ;

Robbiati, SF ;

Frontini, L ;

Piazza, E ;

Ianniello, GP ;

Veltri, E ;

Castiglione, F ;

Rosetti, F ;

Gebbia, V ;

Seymour, L ;

Chiodini, P ;

Perrone, F .

LANCET ONCOLOGY, 2005, 6 (09) :669-677

[10]

DOUILLARD JY, 2005, ASCO WEB SITE

← 1 2 3 4 5 →